Press

November 2025, Kalm Therapeutics wins $100,000 Launchpad Award.

October 2025, Kalm Therapeutics adds Dr. Peter Lio to the team.

August 2025, Kalm Therapeutics raises capital for conducting a Phase 1b clinical trial in atopic dermatitis patients

March 2025, Southern Research Awards Therapeutics Development Fund Grant to Kalm Therapeutics

October 2024, NIH Awards $1.6M Grant Towards Kalm Patch Development

SEPTEMBER 2024, Kalm adds former GSK Director, Dr. Tomoko Maeda-Chubachi, to the team as Chief Medical Officer

AUGUST 2024, Kalm adds veteran drug developer, Dr. Tacey Viegas, to the team as Chief Development Officer. 

AUGUST 2024, Kalm announces oversubscribed seed round.  

JULY 2024, Kalm CEO, Chris Seibert, interviewed at BIO International 2024 (San Diego).

March 2025, Southern Research Awards Therapeutics Development Fund Grant to Kalm Therapeutics

October 2024, NIH Awards $1.6M Grant Towards Kalm Patch Development

SEPTEMBER 2024, Kalm adds former GSK Director, Dr. Tomoko Maeda-Chubachi, to the team as Chief Medical Officer

AUGUST 2024, Kalm adds veteran drug developer, Dr. Tacey Viegas, to the team as Chief Development Officer. 

AUGUST 2024, Kalm announces oversubscribed seed round.  

JULY 2024, Kalm CEO, Chris Seibert, interviewed at BIO International 2024 (San Diego).